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Trivalent and pentavalent forms of inorganic
arsenic are ubiquitous elements found in
nature that result in signiﬁcant human expo-
sure. Dermal or pulmonary exposure to
arsenic can also occur occupationally in the
mining/smelting, agriculture, or micro-
electronics industries (Enterline and Marsh
1982; Wall 1980). Although historically
arsenic is considered a potent human hazard
because of its neoplastic outcomes, increasing
epidemiologic evidence indicates a link
between arsenic exposure and risk to vascular
diseases related to atherosclerosis. Increased
mortality from ischemic heart disease was ﬁrst
reported in copper smelter workers exposed
to arsenic (Axelson et al. 1978; Lee and
Fraumeni 1969; Welch et al. 1982). Further,
exposure to arsenic in artesian well water has
been associated with blackfoot disease as well
as increased mortality from cardiovascular
diseases (Chen et al. 1996, 1988; Wu et al.
1989). Blackfoot disease clinically and patho-
logically resembles severe peripheral arte-
riosclerosis, such as Burger’s disease (Tseng
1989). Recently, a dose–response relationship
between carotid atherosclerosis and long-term
exposure to arsenic in drinking water has
been reported in a population with blackfoot
disease, with researchers using ultrasono-
graphic evaluation of the superficial carotid
artery (Wang et al. 2002). Arsenic-related
ischemic heart diseases in humans have not
been related to atherogenic serum lipid pro-
ﬁles (Hsueh et al. 1998), and the underlying
pathophysiologic mechanisms are still not
established.
Progress in understanding risk factors
leading to atherosclerosis has resulted from
the development of specific genetic mouse
models that make the mouse—which nor-
mally is very resistant to atherosclerosis—
highly susceptible to this disease. One of
these models is deﬁciency of the gene coding
apolipoprotein E (ApoE), the primary ligand
for removal of plasma lipoproteins from
the blood. ApoE deficiency leads to severe
atheroma formation remarkably similar in
anatomical predilection and histopathologic
features to human atherosclerosis (Nakashima
et al. 1994; Palinski et al. 1994). Although
different risk factors may modulate athero-
genesis, a series of critical events including
endothelial dysfunction/activation, oxidation
of lipids, and smooth-muscle cell prolifera-
tion are currently considered major patho-
genic mechanisms required for atheroma
formation and acceleration (Ross 1999). In
this study, we determined whether arsenic
exposure inﬂuences the progression of athero-
sclerotic plaque formation in ApoE–/– mice.
Further, the effects of arsenic on molecular
events relevant to the major pathogenic mech-
anisms of atherosclerosis were evaluated in
human vascular cell culture systems.
Materials and Methods
Experimental animals. Female B6.129P2-
ApoE mice and female C57BL6 mice were
obtained from Jackson Laboratory (Bar
Harbor, ME). All animals were housed in
polycarbonate cages containing hardwood chip
bedding at room temperature (21 ± 2°C) on a
12-hr light/dark cycle and were provided chow
and water ad libitum. Groups of 4-week-old
mice were provided 20 or 100 µg/mL sodium
arsenite (Sigma Chemical Co., St Louis, MO)
in their drinking water for up to 24 weeks. The
mice were fed under two regimens: regimen 1,
a commercial mouse chow diet (LM-485;
Harlan, Indianapolis, IN); or regimen 2, regu-
lar chow followed by a cocoa butter diet for
2 weeks (15.8% fat; TD 88051; Harlan).
Preparation of mouse aortas and quantiﬁ-
cation of atherosclerosis. After blood collection,
mice were sacriﬁced by CO2 asphyxiation, and
the aortic tree was perfused for 10 min with
ice-cold phosphate-buffered saline containing
20 mM butylated hydroxytoluene (BHT)
and 2 mM ethylenediaminetetraacetic acid
(EDTA) (pH 7.4) by inserting a cannula into
the left ventricle and allowing free efﬂux from
an incision in the vena cava. To allow for ﬁxa-
tion, perfusion was continued for 10 min with
formal–sucrose (4% paraformaldehyde, 5%
sucrose, 20 mM BHT, and 2 mM EDTA,
pH 7.4). The aorta and its main branches were
dissected from the aortic valve to the iliac
bifurcation. After removal of the surrounding
adventitial tissue, the aorta was opened longi-
tudinally and stained with Sudan IV. The
extent of atherosclerosis was determined by
using the en face method, as described previ-
ously (Nakashima et al. 1994; Palinski et al.
1994). Quantitative analysis of the lesion size
was performed by ﬁrst capturing aorta images
with a Sony DXC-960MD three-chip charge-
coupled device color video camera (Sony,
Tokyo, Japan) connected to an Olympus
SZX12 dissection microscope (Olympus,
Melville, NY) and then analyzing the data with
Simple 32 software (Imaging Systems,
Cranberry Township, PA).
Arsenic determination in tissues. The aor-
tic tree and heart from control or arsenic-
treated mice were quick-frozen in acid-free
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August 2003]vials and stored at –70°C. The tissue samples
were digested by addition of 6 N HCl at
80°C for 16 hr in a specially designed reac-
tion vessel. Analyses of arsenic tissue levels
were performed by Battelle Marine Sciences
Lab (Seqium, WA) using an atomic absorp-
tion method (Crecelius 1998). Quality con-
trol was established through calibration and
testing of the hydride generation, purging,
and detection systems.
Cell cultures. Cryopreserved, primary
human aortic endothelial cells (HAECs) and
aortic smooth muscle cells (AoSMC) were pur-
chased from Clonetics Corp. (San Diego, CA)
and grown in 25-cm2 tissue culture flasks in
endothelial cell-growth medium (EGM-2) or
smooth-muscle growth medium (SmGM-2),
respectively, supplied by Clonetics Corp. The
cells were grown at 37°C in a humidiﬁed, 95%
air/5% CO2 atmosphere.
Nuclear extracts and electrophoresis
mobility shift assay. Nuclear proteins were
prepared from aliquots of 1 × 107 cells accord-
ing to the method of Schreiber et al. (1989).
DNA binding reactions and electrophoresis
mobility shift assays (EMSAs) were performed
as described previously (Simeonova et al.
1997). Briefly, the 5´ ends of the double-
stranded oligonucleotides were labeled with 
γ-32P-ATP (New England Nuclear/Dupont,
Boston, MA), using 6–10 U of T4 poly-
nucleotide kinase (USB/Amersham, Cleveland,
OH). Binding reactions (30 µL) were per-
formed on ice for 30 min in reaction mixtures
containing 10 µg nuclear proteins, 20 mM
Tris-HCl (pH 7.8), 100 mM NaCl, 5 mM
MgCl2, 1 mM EDTA, 5 mM dithiothreitol,
50 µg/mL bovine serum albumin, 2 µg
poly(dI-dC)⋅poly(dI-dC), 10% glycerol, and
approximately 0.1 ng (2 × 105 cpm) speciﬁed
probe. For detection of activating protein
(AP)-1 DNA-binding activity, an oligonu-
cleotide was obtained from Santa Cruz (Santa
Cruz, CA) containing a consensus sequence of
AP-1 (5´-CGC TTG ATG ACT CAG CCG
GAA-3´) or nuclear factor (NF)-κB (5´-AGT
TGA GGG GAC TTT CCC AGG C-3´).
Protein-DNA complexes were separated on a
5% nondenaturing polyacrylamide gel. Gels
were electrophoresed at 125 V in 50 mM
Tris–50 mM boric acid/1 mM EDTA, dried,
and autoradiographed overnight. The auto-
radiograms were scanned with a computerized
laser densitometer (Eagle Eye II Image Analysis
System, Stratagene, La Jolla, CA). These
results were examined using One Dscan gel
analysis software (Scanalytics, Fairfax, VA).
For characterization of DNA binding activity,
nuclear protein extracts were preincubated for
1 hr before adding labeled probe, with either
excess unlabeled oligomers or 2 µg/mL anti-
bodies to different subunits of the AP-1 or
NF-κB family (Santa Cruz Biotechnology,
Santa Cruz, CA).
Gene expression studies. RNA from cell
cultures was extracted using the Rneasy total
RNA kit (Qiagen, Santa Clarita, CA). RNA
purity and concentration were assessed by
determining A260/A 280 absorption. cDNA was
synthesized from 1 µg RNA. Conventional
reverse transcriptase (RT)-PCR ampliﬁcation
was performed as previously described
(Simeonova et al. 1997), using PCR primers
for glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) and interleukin 8 (IL-8) (Clontech
Laboratories Inc., Palo Alto, CA). The PCR
products were visualized by ultraviolet illu-
mination after electrophoresis through 2.0%
agarose (Ultra-Pure, Sigma) at 60 V for
80 min and staining in Tris borate/EDTA
buffer (89 mmol/L Tris, 89 mmol/L boric
acid, 2.5 mmol/L EDTA, pH 8.2) containing
0.5 mg/mL ethidium bromide. Real-time PCR
for IL-8 and 29S/rRNA were performed using
predeveloped primers and probes (TaqMan
assay reagents; PE Applied Biosystems, Foster
City, CA) on an ABI Prism 7700 Sequence
detector (PE Applied Biosystems). This
method involved obtaining CT values for the
transcript of interest, normalizing to the
housekeeping gene 29S/rRNA and comparing
the relative increases between control and
experimental samples.
Low-density lipoprotein oxidation. We
incubated 200 µg/mL sterile human plasma
low-density lipoprotein (LDL; Calbiochem,
La Jolla, CA) with HAECs for 3 or 24 hr
in serum-free medium. Simultaneously with
LDL exposure, the cells were treated with
20 µM CuSO4, 250 µM H2O2, or 2–50 µM
sodium arsenite. The oxidation state of
LDL was assayed by determining thiobarbi-
turic acid–reactive substances using a com-
mercially available kit (LPO-586; R&D,
Minneapolis, MN).
Cell mitogenesis. Human AoSMCs were
seeded in 96-well, flat-bottomed culture
plates at a concentration of 1 × 103 cells/well.
The next day (~40% confluent) the culture
media were replaced with basal media (with-
out growth factors), and the cells were
exposed to concentrations of sodium arsenite
for 48–72 hr. During the last 4 hr of incuba-
tion, 3H-thymidine (6.7 Ci/mmol; New
England Nuclear/DuPont, Boston, MA) was
added at a concentration of 0.5 µCi/well. The
cells were detached from the plates by addi-
tion of 0.1% trypsin and collected onto glass-
ﬁber ﬁlters using an automated cell harvester
(Skatron, Sterling, VA). Cellular incorpora-
tion of 3H-thymidine was determined by
liquid scintillation counting.
Statistical analysis. All experiments were
replicated, and representative findings are
shown. Statistical signiﬁcance was determined
by one-way analysis of variance. When the 
F-value was signiﬁcant, the means were com-
pared using Fisher’s post hoc analysis.
Results
To evaluate the effects of arsenic exposure on
atherogenicity, female ApoE–/– or C57BL/6
wild-type mice were exposed to sodium arsen-
ite in drinking water for 24 weeks and fed
either regular chow (regimen 1) or a regular
chow for 22 weeks followed by a cocoa butter
(fat) diet for 2 weeks (regimen 2). Controls
received water not containing arsenic. Arsenic
exposure enhanced atherosclerotic lesion for-
mation in ApoE–/– mice under both diet regi-
mens, compared with nonarsenic control
groups. Wild-type C57BL/6 animals exposed
to 100 µg/mL arsenic for 24 weeks and fed
diet regimen 2 did not develop atherosclerotic
lesions (Figure 1E and F). Sudanophilic
lipid–rich lesions in ApoE–/– mice were typi-
cally found in the vicinity of the aortic valve
and the small curvature of the arch at the
aortic root. Because among the individual seg-
ments of the same aorta, the smallest coeffi-
cient of variation occurred in the segment
that contained the most extensive lesions
(Palinski et al. 1994), the thoracic part of the
aorta was used for quantitative assessment.
Quantitative computer-assisted image analysis
revealed a dose-dependent increase in the area
of aortic lesions (Figure 2). For example, in
mice provided diet regimen 2, the 20 or 100
µg/mL concentrations of sodium arsenite
induced an average 1.6- fold and 2.3-fold
increase (p < 0.02) in the lesion size, respec-
tively, compared with controls under the
same regimen. Introduction of the fat diet for
2 weeks (regimen 2) resulted in slight but not
significant increases of the atherosclerotic
lesion area in both control and experimental
mice exposed to arsenic.
Body weight and serum cholesterol levels
were not significantly different between
arsenic and control animals administered a
regular diet (Table 1). Substitution of the
regular diet with a high-fat diet for 2 weeks
(regimen 2) resulted in a marked increase in
cholesterol levels in control and arsenic-treated
mice but no significant differences in body
weight. Exposure to 20 µg/mL sodium arsen-
ite had no additional effect on cholesterol lev-
els in mice receiving regimen 2, whereas
exposure to 100 µg/mL sodium arsenite
induced a slight but significant increase
(p < 0.02) in the serum cholesterol levels com-
pared with the control mice.
To evaluate whether atherosclerosis pro-
gression is associated with accumulation of
arsenic in the cardiovascular tissue, atomic
absorption analysis was conducted. ApoE–/–
mice that received 20 or 100 µg/mL sodium
arsenic for 24 weeks showed a dose-dependent
increase in total arsenic tissue accumulation,
representing a 5-fold and 8.5-fold increase,
respectively. (Figure 3A). Arsenic tissue accu-
mulation depended on the exposure duration
because at 12 weeks signiﬁcant accumulation
Article | Vascular effects of arsenic
Environmental Health Perspectives • VOLUME 111 | NUMBER 14 | November 2003 1745was observed only with the high concentra-
tions of arsenic (100 µg/mL). ApoE–/– and
C57BL/6 wild-type mice demonstrated similar
arsenic tissue levels at least during the 12 weeks
of arsenic exposure (Figure 3B).
To evaluate whether arsenic induces events
in endothelial cells relevant to atherogenic
potential, we used HAEC cultures. Because
oxidative modifications of lipoproteins in
artherial tissue are a widely accepted hypothesis
of atherogenesis (Steinberg et al. 1989), and
because arsenic can alter the cellular redox state
[reviewed by Pi et al. (2002)], the effect of
arsenic on LDL oxidation was examined.
Incubation of endothelial cells with sodium
arsenite (2–50 µM), in contrast to treatment
with CuSO4 or H2O2, did not modify LDL
oxidation, as measured by melonaldehyde
(MDA) formation (Figure 4A). Furthermore,
CuSO4, but not arsenic, increased H2O2-
induced MDA formation indicating that under
these experimental conditions arsenic does not
effect the oxidation state of LDL. Neointimal
monocyte inﬁltration is an important early step
in atheroma formation, mediated in part by
inflammatory mediators such as adhesion
molecules and chemokines, including IL-8
[reviewed by Ross (1999)]. To evaluate
whether arsenic modulates the expression of
inflammatory mediators, RNA was prepared
from arsenic-treated endothelial cells and
examined by reverse transcriptase PCR
(RT-PCR) for IL-8 gene expression (Figure
4B). We obsersved a dose-dependent increase
in IL-8 mRNA transcripts at 2 and 5 hr after
arsenic treatment. These results were con-
ﬁrmed and statistically analyzed by real-time
RT-PCR (Figure 4C). IL-8 expression was sig-
niﬁcantly induced by arsenic without signiﬁ-
cant changes in the housekeeping gene (29S).
EMSAs were conducted to determine whether
the increased expression of IL-8 was associated
with DNA binding activity of the major tran-
scription factors responsible for their regulation,
AP-1 and NF-κB. Endothelial cells exposed to
5 or 50 µM sodium arsenite showed a dose-
dependent increase in AP-1 and NF-κB DNA
binding activity (Figure 4C). Tumor necrosis
factor (TNF)-α was used as a positive control.
In connection with the role of smooth
muscle cell proliferation in atherosclerosis
[reviewed by Ross (1999)], and cell-growth
potential of arsenic demonstrated previously
for human keratinocytes and uroepithelial cells
(Germolec et al. 1998; Simeonova et al. 2000),
the effect of arsenic on AoSMC proliferation
was evaluated. Exposure to sodium arsenite for
72 hr did not induce an increase in thymidine
uptake, whereas platelet-derived growth factor
(PDGF), used as a positive control, induced a
signiﬁcant increase in the mitogenic activity of
AoSMCs under the same conditions. The
thymidine uptake (cpm) of cells untreated,
treated with arsenic at 0.1, 0.5, and 2 µM, or
treated with PDGF at 10 ng/mL, was 1,593 ±
115, 1,576 ± 76, 1,627 ± 156, 1,051 ± 129,
and 4,182 ± 171, respectively.
Discussion
ApoE–/– mice have been used extensively to
study the development of atherosclerotic lesions
and to identify potential risk factors. The wide
acceptance of this model is largely based on its
ability to produce lesions that show similarities
in distribution and histopathologic characteris-
tics to those found in humans (Breslow 1996).
Although the quantiﬁcation of atherosclerosis
has been the source of considerable debate, the
en face method in mice has been well character-
ized and is generally accepted (Nakashima et al.
1994; Palinski et al. 1994). This model has
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Figure 1. Photomicrographs of representative Sudan IV–stained aortas (a tho-
racic section and a whole aorta) from mice administered arsenic for 24 weeks.
In each panel, the top photomicrograph portrays the thoracic section, and the
bottom the whole aorta. (A) ApoE–/– mice fed regimen 1 and receiving control
drinking water. (B) ApoE–/– mice fed regimen 1 and receiving drinking water
containing sodium arsenite (100 µg/mL). (C) ApoE–/– mice fed regimen 2 and
receiving control drinking water. (D) ApoE–/– mice fed diet regimen 2 and
receiving drinking water containing sodium arsenite (100 µg/mL). (E) C57BL/6
mice fed regimen 2 and receiving control drinking water. (F) C57BL/6 mice fed
regimen 2 receiving drinking water containing sodium arsenite (100 µg/mL).
Arrows indicate atherosclerotic plaques. been recently used to evaluate successfully the
atherogenic risk of sidestream cigarette smoke
and angiotensin II (Daugherty et al. 2000;
Gairola et al. 2001; Weiss et al. 2001). Arsenic
exposure, through drinking water, was found
here to increase atheroma formation in ApoE–/–
mice in parallel with increasing levels of arsenic
in the vessel wall. Just as arsenic-related ische-
mic heart diseases in humans are not associated
with serum lipid proﬁles (Hsueh et al. 1998),
exposure of ApoE–/– mice to arsenic accelerated
the atheroma formation without altering cho-
lesterol levels, except when the higher dose of
arsenic was combined with an atherogenic diet.
Introduction of an atherogenic diet for
2 weeks induced severe hypercholesterolemia
without a signiﬁcant effect on the lesion size.
If the atherogenic diet was continued for
longer than 4 weeks, significant increases in
cholesterol blood levels and lesion size were
observed. However, the effect of arsenic on
atherosclerotic lesion size, under these condi-
tions, was diminished probably because it was
masked by the diet effects (data not shown).
The atherogenic effect of arsenic was not
observed in wild-type mice, although they
accumulate similar levels of arsenic in the car-
diovascular tissue. Consistent with this para-
digm, angiotensin II has a strong atherogenic
potential in ApoE–/– mice but cannot trigger
atheroma development in normal mice (Weiss
et al. 2001). The wild-type mice are resistant
to atherosclerosis, but atheroma formation can
be triggered by a long-term (> 24 weeks) high-
fat diet. Under these conditions, arsenic expo-
sure could accelerate the atherogenesis in
C57BL/6 mice. Similarly, it has been suggested
that arsenic accumulates in skin or bladder tis-
sue, major targets of arsenic carcinogenicity,
but acts as a tumor promoter rather than a
complete carcinogen (Germolec et al. 1998;
Rossman et al. 2001).
The mechanisms whereby arsenic acceler-
ates atherosclerosis are probably multifactorial.
In vitro studies with endothelial cell cultures
suggest that arsenic can cause direct endothelial
dysfunction through oxidant formation. For
example, Barchowsky et al. (1996, 1999)
demonstrated that exposure of endothelial cells
to arsenite induces NF-κB activation and
DNA synthesis through reactive oxygen
species, whereas Tsai et al. (2001) showed that
arsenite decreases Fas ligand expression
through oxidant formation. Other investiga-
tors have also demonstrated that arsenic dis-
rupts cell proliferation in endothelial cell
cultures (Chen et al. 1990). Bunderson et al.
(2002) recently reported that arsenic increases
peroxynitrite formation in bovine aortic
endothelial cells as well as the inflammatory
mediator cyclooxygenase-2. We observed
that arsenic induces expression of genes
coding for inﬂammatory mediators including
IL-8 in HAECs. Atherogenesis requires local
chemokine production for regulating migra-
tion and activation of leukocytes. Historically,
IL-8 is a potent neutrophil chemoattractant
(Terkeltaub et al. 1998) but participates in
atherosclerosis as an endothelial growth factor
(Koch et al. 1992) and a chemoattractant of
smooth muscle cells (Yue et al. 1993), T cells
(Lloyd et al. 1996), and monocytes (Gerszten
et al. 1999). The expression of inﬂammatory
mediators by arsenic likely occurs through
activation of transcription factors, including
NF-κB and AP-1. In HAECs, as well as
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Table 1. Body weight and total plasma cholesterol under regimens 1 and 2.
Arsenic
Regimen Control 20 µg/mL 100 µg/mL
Body weight (g) 1 24.3 ± 2.0 26 ± 3.2 23.4 ± 2.4
2 23.0 ± 2.3 23 ± 2.8 22.0 ± 2.2
Cholesterol (mg/dL) 1 634 ± 47 569 ± 45.4 533 ± 9.0
2 3,225 ± 47 3,129 ± 84.3 4,071 ± 438 *
Each value represents the mean ± SE of 10 animals.
*p < 0.01.
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Figure 3. Arsenic levels in cardiovascular tissue.
The data are presented as n-fold change from the
control levels (ApoE 0.024 ± 0.002 and C57BL/6 0.03 ±
1.2 µg/g tissue). Each value represents the mean ±
SE of four animals. (A) ApoE–/– mice fed regimen 1
receiving control drinking water or water containing
20 and 100 µg/mL sodium arsenite (As) for 24 weeks.
(B) ApoE and C57BL/6 mice fed regimen 1 receiving
control drinking water or water containing 20 and
100 µg/mL sodium arsenite (As) for 12 weeks.
*p < 0.001.
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Figure 4. Evaluation of arsenic-induced cellular
effects related to atherogenesis. (A) Effect of sodium
arsenite on LDL oxidation in HAECs. Cells were cul-
tured in serum-free medium containing 200 µg/mL
LDL for 3 hr. CuSO4 (20 µM), H2O2 (250 µM), or sodium
arsenite (10 µM) was simultaneously added. The oxi-
dation state of LDL was assayed by the determination
of MDA formation and the results presented as an n-
fold increase from the control (LDL). Each value rep-
resents the mean ± SE of four cultures. (B) RT-PCR
analysis of IL-8 expression in HAECs treated for 2 or 5
hr with sodium arsenite. Cultures were performed in
quadruplicate, and representative samples are
shown. (C) Real-time PCR analysis of IL-8 gene
expression normalized to the 29S/rRNA expression
from corresponding samples. Each value represents
the mean ± SE of four cultures. (D) NF-κB and AP-1
DNA binding activity in HAECs treated with sodium
arsenite. Nuclear extracts from control or arsenic-
treated cells (micromoles) were evaluated by EMSA
using a 32P-labeled double-stranded oligonucleotide
probe. As a positive control, cells were treated for 1
hr with human recombinant TNF-α (100 ng/mL) and
evaluated by EMSA.
*p < 0.001.
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Figure 2. Percentage of aortic lesion areas in ApoE–/–
mice fed regimen 1 or regimen 2 and receiving con-
trol drinking water or water containing sodium
arsenite (As) at concentrations of 20 and 100 µg/mL.
Each value represents the mean ± SE of 10 animals.
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keratinocytes and urinary bladder cells
(Barchowsky et al. 1996; Burleson et al. 1996;
Simeonova et al. 2000), arsenic is a potent
activator of AP-1 and NF-κB DNA binding
activity. Furthermore, AP-1 and NF-κB can
regulate IL-8 expression, because the IL-8 gene
contains multiple binding sites for these tran-
scription factors (Ahmad et al. 1998), and both
are subject to redox-dependent regulation
(Flohe et al. 1997).
The afﬁnity of inorganic arsenic for vici-
nal sulfhydryl groups is thought to be respon-
sible for arsenic accumulation in tissues rich
in sulfhydryl-containing molecules (Lindgren
et al. 1982; Yamauchi and Yamamura 1983).
We demonstrated that arsenic accumulates in
the cardiovascular tissue, and this could be
a prerequisite for endothelial dysfunction.
Consistently, tissue accumulation through
sulfhydryl interactions has been suggested to be
involved in arsenic-mediated skin and bladder
toxicity [reviewed by Simeonova and Luster
(2000, 2002)]. Alternatively, it is possible that
arsenic induces endothelial dysfunction by
indirect mechanisms. In this respect, arsenic
has been shown to modulate the coagulation
status by enhancing the aggregation activities
of platelets (Lee et al. 2002). Another factor
responsible for atherogenicity is oxidative
modiﬁcations of LDL (Steinberg et al. 1989).
Free transition metal ions, such as copper, have
been shown, although only in vitro, to stimu-
late the lipoprotein oxidation by endothelial
cells (Witztum and Steinberg 1991). Although
arsenic is not a transition metal, it has been
demonstrated to have oxidative potential,
including induction of reactive oxygen species
in porcine aortic endothelial cells (Barchowsky
et al. 1999). However, we were unable to
demonstrate that arsenic, in contrast to copper
ion or hydrogen peroxide, modulates the oxi-
dation of LDL in aortic endothelial cells.
In conclusion, exposure to arsenic in drink-
ing water accelerates the atherosclerosis forma-
tion in ApoE–/– mice, and this effect is
accompanied with arsenic accumulation in the
vessel wall. Although endothelial cell activation
is a potential mechanism in arsenic-related vas-
cular effects, the precise mechanisms, especially
the role of oxidative stress, need to be further
evaluated.
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